LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: An application of polarity switching and monolithic HPLC column

Bioanalysis

Volumn 6, Issue 15, 2014, Pages 2071-2082

  Pursley, Janice ^a   Shen, Jim X ^a   Schuster, Alan ^a   Dang, Oanh T ^b   Lehman, Jim ^b   Buonarati, Michael H ^b   Song, Yan ^a   Aubry, Anne Francoise ^a   Arnold, Mark E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Intertek   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; BMS 730823; CITRATE SODIUM; DRUG METABOLITE; METHANOL; SILICON DIOXIDE; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACCURACY; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; EQUIPMENT DESIGN; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPH; MASS SPECTROMETER; PROCESS CONTROL; PROCESS DESIGN; PROCESS DEVELOPMENT; PROCESS MONITORING; PROCESS OPTIMIZATION; PROCESS TECHNOLOGY; PUMP; QUALITY CONTROL; REPRODUCIBILITY; SAMPLER; SEPARATION TECHNIQUE; SPECTRAL SENSITIVITY; STANDARD; SYSTEM ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS; BLOOD; DEVICES; PROCEDURES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FACTOR XA INHIBITORS; HUMANS; PYRAZOLES; PYRIDONES; TANDEM MASS SPECTROMETRY;

EID: 84908018905     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/BIO.14.66     Document Type: Article

References (23)

1. Srinivas NR, Mullangi R. An overview of various validated HPLC and LC-MS/MS methods for quantitation of drugs in bile: challenges and considerations. Biomed. Chromatogr. 25(1-2), 65-81 (2011).
2. Aubry AF. LC-MS/MS bioanalytical challenge: ultra-high sensitivity assays. Bioanalysis 3(16), 1819-1825 (2011). • General review of recent progress in bioanalysis.
3. Xu RN, Fan L, Rieser MJ, El-Shourbagy TA. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J. Pharm. Biomed. Anal. 44(2), 342-355 (2007).
4. Pinto DJ, Orwat MJ, Koch S et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl) phenyl)-4,5,6,7-tetrahydro-1H -pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50(22), 5339-5356 (2007). • Therapeutic use of apixaban. Including a synthetic route for apixaban.
5. Agrawal R, Jain P, Dikshit SN. Apixaban: a new player in the anticoagulant class. Curr. Drug Targets 13(6), 863-875 (2012).
6. Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR. Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J. Enzyme Inhib. Med. Chem 26(4), 514-526 (2011).
7. Pinto DJ, Qiao JX, Knabb RM. The emergence of factor Xa inhibitors for the treatment of cardiovascular diseases: a patent review. Expert Opin. Ther. Pat. 22(6), 645-661 (2012).
8. Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann. Pharmacother. 45(10), 1262-1283 (2011).
9. Barrett YC, Wang J, Knabb R, Mohan P. Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis. Thromb. Haemost. 105(1), 181-189 (2011).
10. Wong PC, Crain EJ, Watson CA, Xin B. Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits. J Thromb Haemost 7(8), 1313-1320 (2009).
11. Wong PC, Crain EJ, Xin B et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J. Thromb. Haemost. 6(5), 820-829 (2008).
12. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb. Hemost. 104(2), 302-310 (2010).
13. Raghavan N, Frost CE, Yu Z et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos. 37(1), 74-81 (2009). •• Metabolism of apixaban, PK in human subjects.
14. Barrett YC, Wang J, Song Y et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb. Haemost. 107(5), 916-924 (2012). • Metabolism of apixaban, drug-drug interaction.
15. Frost C, Wang J, Nepal S et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol. 75(2), 476-487 (2013). • Metabolism of apixaban, PK, PD and food effect.
16. Delavenne X, Mismetti P, Basset T. Rapid determination of apixaban concentration in human plasma by liquid chromatography/tandem mass spectrometry: Application to pharmacokinetic study. J. Pharm. Biomed. Anal. 78-79, 150-153 (2013). • Bioanalytical method for the quantitation of apixaban in human plasma.
17. Federal Register, TITLE 21, PART 58, Good laboratory practice for nonclinical laboratory studies.
18. Booth B. When do you need a validated assay? Bioanalysis 3(24), 2729-2730 (2011).
19. Booth B. Incurred sample reanalysis. Bioanalysis 3(9), 927-928 (2011).
20. Shen JX, Wang H, Tadros S, Hayes RN. Orthogonal extraction/chromatography and UPLC, two powerful new techniques for bioanalytical quantitation of desloratadine and 3-hydroxydesloratadine at 25 pg/ml. J. Pharm. Biomed. Anal. 40(3), 689-706 (2006). •• Use of SPE clean-up followed by high-resolution chromatography in bioanalysis.
21. Smith JH, Mcnair HM. Fast HPLC with a silica-based monolithic ODS column. J. Chromatogr. Sci. 41(4), 209-214 (2003).
22. Samanidou VF, Ioannou AS, Papadoyannis IN. The use of a monolithic column to improve the simultaneous determination of four cephalosporin antibiotics in pharmaceuticals and body fluids by HPLC after solid phase extraction - a comparison with a conventional reversedphase silica-based column. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 809(1), 175-182 (2004). •• Report on the use of monolithic column in bioanalysis.
23. Fast D, Kelley M, Viswanathan CT et al. Workshop Report and Follow-Up - AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples: implications of Crystal City Recommendations. AAPS J. 11(2), 238-241 (2009).